This study suggests that the use of ACE inhibitors and DPP-4 inhibitors, which inhibit the degradation of substance P and bradykinin, in the clinic tend to have different effects on the onset of vasoactive peptide-induced angioedema. This evidence concerns the gene KNG1 and angioedema.